Skip to Content

'
Dean Anthony Lee, MD, PHD

Present Title & Affiliation

Dual/Joint/Adjunct Appointment

Faculty, Graduate School of Biomedical Sciences, The University of Texas Health Sciences Center, Houston, TX

Bio Statement

Contact Information

Phone- 713-563-5404

Email- dalee@mdanderson.org


Clinical Focus

My clinical practice is in caring for children undergoing hematopoietic stem cell transplantation (HSCT) for malignant or non-malignant diseases.  My clinical research is focused on developing trials of adoptive immune therapy with NK cells, particularly for myeloid malignancies within the context of transplant.  I also participate in clinical trials of autologous HSCT for neurologic injuries.  Investigator-initiated clinical trials that are open or in development include

- a phase I clinical trial for reinduction of AML using haploidentical NK cells and a fusion protein called ALT-801- produced by Altor BioSciences- that targets NK cells to cells that express p53

- a phase I clinical trial testing the safety and feasibility of IL-21-expanded NK cells (developed in my laboratory) in combination with FLAG chemotherapy for reinduciton of AML

- a phase I clinical trial testing the safety and feasibility of IL-21-expanded NK cells in combination with transplant for AML

- a phase I clinical trial testing the safety and feasibility of IL-21-expanded NK cells in combination with rituximab and lenalidomide for lymphoma

- a phase I clinical trial testing the safety and feasibility of IL-21-expanded NK cells in combination with anti-GD2 mAb for neuroblastoma

 

Laboratory Focus

Congruent with my clinical practice and clinical research, my laboratory research is focused on improving NK-cell immunotherapy against cancer and understanding NK cell biology, based on a system of ex vivo NK cell expansion, based on genetically-engineered artificial APCs expressing a membrane-bound IL-21 fusion.  This system enables our research in the following key areas:

* Adoptive immunotherapy of pediatric cancers

* Ex vivo epanded and gene-modified NK cells

* STAT3 signaling in NK cells

* post-maturation KIR licensing and repertoire molding

* Chimeric antigen receptors designed with NK-cell like endodomain signaling

* Platforms and devices for non-integrating (mRNA) gene transfer

* Transposon-based gene modification of NK cells

* Immunomodulatory drugs to enhance NK cell function

* Trogocytosis for non-genetic modification of NK cells


UT Graduate School website: http://gsbs.uth.tmc.edu/tutorial/lee_d.html

PubMed publication list: http://www.ncbi.nlm.nih.gov/sites/myncbi/collections/public/1F_CsFkIaUGdcSy2889Vmwo/

 

Collaborative Research Program

We work closely with the laboratory of Laurence Cooper and collaborate with many other investigators in academia and industry. The goals of these collaborations are always to advance the field of cellular immunotherapy and translate those advancements to improved long-term, disease-free survival of patients with pediatric malignancies and hematologic diseases.

 

Lab Meeting

Friday 9 A.M. in SCRB1 Conference Room

 

Current Lab Members

* Cecele Denman (Senior Research Associate)

* Marie Fouad (Undergrad student)

* Anitha Gururajan, MS

* Prasad Phatarpekar (PhD Student, GSBS)

* Anish Ray, MD (Clinical Postdoctoral Fellow)

* Howard Rossoff (PhD Student, GSBS)

* Vladimir Senyukov, PhD (Research Investigator)

* Srinivas Somanchi, PhD (Research Investigator)


Lab Alumni (When in my lab -> Current location):

William Choi (Undergrad, Houston Baptist University -> MD/PhD Student, Baylor College of Medicine)

Nichole Corless (Undergrad, Fresno Pacific University -> Graduate School, CSU Fresno)

Santiago De La Garza (High School Student -> Medical Student, Baylor College of Medicine)

MariRene Font (High School Student -> Undergrad, Notre Dame)

Jeff Friesen (Undergrad, Fresno Pacific University -> School of Medicine, UC Irvine)

David Fujihara (Undergrad, Fresno Pacific University -> Undergrad, Fresno Pacific University)

Jonathan Hanna (High School Student -> Undergrad, Duke University)

Jennifer Johnson (Undergrad, Fresno Pacific University -> School of Medicine, St. Louis Univ)

Tim Kahn (Undergrad, Fresno Pacific University -> Undergrad, Fresno Pacific University)

Lisa Kopp (Clinical Postdoctoral Fellow -> Assistant Professor, UNM Tucson)

Stephen Lee (High School Student -> Undergrad, Sam Houston State Univ)

Brian Liu (High School Student -> Premed, Johns Hopkins)

Bhavisha Patel (School of Medicine, Univ Illinois -> Medicine Resident, U Wisconsin)

Ivan Petrich (Undergrad, Fresno Pacific University -> Grad School, Univ Utah)

Romina Sabella-River (Clinical Postdoctoral Fellow -> Staff Physician, Texas Children's Pediatric Associates)

Aaron Seo (Undergrad, U Texas -> MD/PhD Student, University of Washington)

David Walker (Undergrad, Carlton College)

Jennifer Williams (Undergrad, Fresno Pacific University -> School of Medicine, Washington Univ)

Shuguo Zhu (Postdoctoral Fellow -> Assistant Professor, Shanghai Jiao Tong University)

Education & Training

Degree-Granting Education

1996 Loma Linda University, Loma Linda, CA, MD, Medicine
1995 Loma Linda University, Loma Linda, CA, PHD, Microbiology and Molecular Genetics
1987 Fresno Pacific College, Fresno, CA, BA, Natural Sciences

Postgraduate Training

7/2000-6/2003 Fellowship, Pediatric Hematology/Oncology, Baylor College of Medicine, Houston, TX, David G. Poplack
7/1996-6/1999 Residency, Pediatrics, Loma Linda University, Loma Linda, CA, Richard E. Chinnock

Board Certifications

11/2004 American Board of Pediatrics: Pediatric Hematology/Oncology
10/1999 American Board of Pediatrics: General Pediatrics

Experience/Service

Other Appointments/Responsibilities

Steering Committee Member for the Department of Immunology, UT MD Anderson Cancer Center, Houston, TX, 4/2012-present
Chief Fellow, Baylor College of Medicine/Texas Children's Hospital, Houston, TX, 7/2002-6/2003
Chief Resident, Loma Linda University Children's Hospital, Loma Linda, CA, 7/1999-6/2000

Institutional Committee Activities

Member, Postdoctoral Advisory Committee (PDAC), UT MD Anderson Cancer Center, 9/2011-present
Member, Institutional Bio-Safety Committee, UT MD Anderson Cancer Center, 9/2011-8/2013
Member, Pediatric Clinical Research SOP Development, The Children's Cancer Hospital of UT MD Anderson Cancer Center, 2011
Chair, Policy CLN0508 Revision Committee, UT MD Anderson Cancer Center, 2008-2009
Member, Clinical Practice Guidelines Committee, Texas Children's Cancer Center, 2004-2006
Member, Chemotherapy Safety Committee, Texas Children's Cancer Center, 2003-2006
Member, Protocol Review Committee/Data Safety Monitoring Board, Baylor College of Medicine, 2003-2006
Member, Education Committee, Pediatrics Hematology/Oncology Section, Baylor College of Medicine, 2002-2004
Member, Resident Advisory Committee, Loma Linda University Medical Center, 1998-2000

Honors and Awards

2009 Excellent Reviewer Award, Office of Scientific Review, UT MD Anderson Cancer Center
2008-2013 Physician Scientist Program, UT MD Anderson Cancer Center
2005-2010 Young Investigator, Stem Cell Transplant Committee, Children's Oncology Group
2003-2005 ASCO Young Investigator Award, American Society of Clinical Oncology
2003-2004 ASH Clinical Research Training Institute, American Society of Hematology
1999 Hertha Ehlers Resident Award of Excellence, Loma Linda University
1998 Junior Resident of the Year Award, Loma Linda University
1995 National Student Research Forum, Galveston, Texas
1992-1993 Selma Andrews Fellowship, Loma Linda University
1992 Student Research Grant, Walter E. MacPherson Society
1987-1989 Graduate Fellowship, California State
1987 Alpha Chi Honor Society, Fresno Pacific College
1983-1987 President's Scholarship, Fresno Pacific College

Professional Memberships

American Society for Clinical Oncology
Member, 2002-present
American Society of Gene Cell Therapy
Member, 2009-present
American Society of Hematology
Member, 2003-present
American Society of Pediatric Hematology/Oncology
Member, 2004-present
Children's Oncology Group, Bethesda, MD
Full Member, 2003-present
International Society for Cell Therapy
Member, 2007-present
JMML Foundation International Working Group
Member, 2008-present
South Plains Oncology Group, Pediatric Scientific Research Council
Member, 2009-present

Selected Publications

Peer-Reviewed Original Research Articles

1. Somanchi SS, Somanchi A, Cooper LJ, Lee DA. Engineering lymph node homing of ex vivo expanded human natural killer cells via trogocytosis of the chemokine receptor CCR7. Blood 119(22):5164-72, 5/2012. e-Pub 4/2012. PMCID: PMC3418772.
2. Kebriaei P, Huls H, Jena B, Munsell M, Jackson R, Lee DA, Hackett PB, Rondon G, Shpall E, Champlin RE, Cooper LJ. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther 23(5):444-50, 5/2012. e-Pub 1/2012. PMCID: PMC3360496.
3. Farhan S, Lee DA, Champlin RE, Ciurea SO. NK cell therapy: targeting disease relapse after hematopoietic stem cell transplantation. Immunotherapy 4(3):305-13, 3/2012. e-Pub 2/2012. NIHMSID: NIHMS5499414.
4. O'Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL, Maiti S, Ma W, Davis RE, Craig S, Lee DA, Champlin R, Wilson H, Cooper LJ. Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep 2:249, 2012. e-Pub 2/2012. PMCID: PMC3278154.
5. Dutour A, Marin V, Pizzitola I, Valsesia-Wittmann S, Lee D, Yvon E, Finney H, Lawson A, Brenner M, Biondi A, Biagi E, Rousseau R. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTLs against CD33+ acute myeloid leukemia (AML). Adv Hematol 2012:683065, 2012. e-Pub 1/2012. PMCID: PMC3261457.
6. Denman CJ, Senyukov VV, Somanchi SS, Phatarpekar PV, Kopp LM, Johnson JL, Singh H, Hurton L, Maiti SN, Huls MH, Champlin RE, Cooper LJ, Lee DA. Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells. PLoS One 7(1):e30264, 2012. e-Pub 1/2012. PMCID: PMC3261192.
7. Jin Z, Maiti S, Huls H, Singh H, Olivares S, Mátés L, Izsvák Z, Ivics Z, Lee DA, Champlin RE, Cooper LJ. The hyperactive Sleeping Beauty transposase SB100X improves the genetic modification of T cells to express a chimeric antigen receptor. Gene Ther 18(9):849-56, 9/2011. e-Pub 3/2011. PMID: 21451576.
8. Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, Mi T, Maiti S, Kebriaei P, Lee DA, Champlin RE, Cooper LJ. Reprogramming CD19-Specific T Cells with IL-21 Signaling Can Improve Adoptive Immunotherapy of B-Lineage Malignancies. Cancer Res 71(10):3516-27, 5/2011. e-Pub 5/2011. PMCID: PMC3096697.
9. Cox CS, Baumgartner JE, Harting MT, Worth LL, Walker PA, Shah SK, Ewing-Cobbs L, Hasan KM, Day MC, Lee D, Jimenez F, Gee A. Autologous bone marrow mononuclear cell therapy for severe traumatic brain injury in children. Neurosurgery 68(3):588-600, 3/2011. PMID: 21192274.
10. Somanchi SS, Senyukov VV, Denman CJ, Lee DA. Expansion, Purification, and Functional Assessment of Human Peripheral Blood NK Cells. J Vis Exp(48), 2011. e-Pub 2/2011. PMCID: PMC3180743.
11. Choi Y, Yuen C, Maiti SN, Olivares S, Gibbons H, Huls H, Raphael R, Killian TC, Stark DJ, Lee DA, Torikai H, Monticello D, Kelly SS, Kebriaei P, Champlin RE, Biswal SL, Cooper LJ. A High Throughput Microelectroporation Device to Introduce a Chimeric Antigen Receptor to Redirect the Specificity of Human T cells. Biomed Microdevices 12(5):855-63, 10/2010. PMID: 20574820.
12. Das CM, Zage PE, Taylor P, Aguilera D, Wolff JE, Lee D, Gopalakrishnan V. Chromatin remodeling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines. Eur J Cancer 46(15):2771-80, 10/2010. PMCID: PMC3025305.
13. Davies JK, Singh H, Huls H, Yuk D, Lee DA, Kebriaei P, Champlin RE, Nadler LM, Guinan EC, Cooper LJ. Combining CD 19-redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies. Cancer Res 70(10):3915-3924, 5/2010. e-Pub 4/2010. PMCID: PMC2873153.
14. Zhu S, Lee DA, Li S. IL12 and IL27 sequential gene therapy via intramuscular electroporation. J Immunol 184(5):2348-2354, 3/2010. e-Pub 2/2010. PMCID: PMC2824785.
15. Lee DA, Verneris MR, Campana D. Acquisition, preparation, and functional assessment of human NK cells for adoptive immunotherapy. Methods Mol Biol 651:61-77, 2010. PMID: 20686960.
16. Frugé E, Margolin J, Horton T, Venkateswaran L, Lee D, Yee DL, Mahoney D. Defining and managing career challenges for mid-career and senior stage pediatric hematologist/oncologists. Pediatr Blood Cancer 55(6):1180-4, 2010. PMID: 20589622.
17. Hurton LV, Siddik RI, Singh H, Olivares S, Rabinovich BA, Tian R, Mojsilovic D, Hildebrand W, Lee DA, Kelly SS, Champlin R, Shpall EJ, Fernandez-Vińa M, Cooper LJ. Identifying candidate allogeneic NK-cell donors for hematopoietic stem-cell transplantation based on functional phenotype. Leukemia 24(5):1059-62, 2010. PMID: 20164852.
18. Manuri PV, Wilson MH, Maiti SN, Mi T, Singh H, Olivares S, Dawson MJ, Huls H, Lee DA, Rao PH, Kaminski JM, Nakazawa Y, Gottschalk S, Kebriaei P, Shpall EJ, Champlin RE, Cooper LJ. piggyBac transposon/transposase system to generate CD19-specific T cells for treatment of B-lineage malignancies. Hum Gene Ther 21(4):427-37, 2010. PMCID: PMC2938363.
19. Meyer C, Kowarz E, Hofmann J, Renneville A, Zuna J, Trka J, Ben Abdelali R, Macintyre E, De Braekeleer E, De Braekeleer M, Delabesse E, de Oliveira MP, Cavé H, Clappier E, van Dongen JJ, Balgobind BV, van den Heuvel-Eibrink MM, Beverloo HB, Panzer-Grümayer R, Teigler-Schlegel A, Harbott J, Kjeldsen E, Schnittger S, Koehl U, Gruhn B, Heidenreich O, Chan LC, Yip SF, Krzywinski M, Eckert C, Möricke A, Schrappe M, Alonso CN, Schäfer BW, Krauter J, Lee DA, Zur Stadt U, Te Kronnie G, Sutton R, Izraeli S, Trakhtenbrot L, Lo Nigro L, Tsaur G, Fechina L, Szczepanski T, Strehl S, Ilencikova D, Molkentin M, Burmeister T, Dingermann T, Klingebiel T, Marschalek R. New insights to the MLL recombinome of acute leukemias. Leukemia 23(8):1490-9, 2009. PMID: 19262598.
20. Singh H, Najjar AM, Olivares S, Nishii R, Mukhopadhyay U, Alauddin M, Manuri PR, Huls H, Lee DA, Dotti G, Bollard C, Simmons PJ, Shpall EJ, Champlin RE, Gelovani JG, Cooper LJ. PET imaging of T cells derived from umbilical cord blood. Leukemia 23(3):620-2, 2009. PMID: 18830258.
21. Lee DA, Tatevian N, Herring RA, McClain KL. EBV+ lymphoproliferative disease following prolonged chemotherapy for refractory LCH. Pediatr Blood Cancer 50(3):728-730, 3/2008. PMID: 17243127.
22. Choi WT, Folsom MR, Azim MF, Meyer C, Kowarz E, Marschalek R, Timchenko NA, Naeem RC, Lee DA. C/EBPbeta suppression by interruption of CUGBP1 resulting from a complex rearrangement of MLL. Cancer Genet Cytogenet 177(2):108-14, 2007. PMID: 17854664.
23. Grupp SA, Frangoul H, Wall D, Pulsipher MA, Levine JE, Schultz KR, [Lee DA]. Use of G-CSF in matched sibling donor pediatric allogeneic transplantation: a consensus statement from the Children's Oncology Group (COG) Transplant Discipline Committee and Pediatric Blood and Marrow Transplant Consortium (PBMTC) Executive Committee. Pediatr Blood Cancer 46(4):414-421 (Cited as COG Transplant Discipline Committee member), 4/2006. PMID: 16463346.
24. Barshes NR, Myers GD, Lee D, Karpen SJ, Lee TC, Patel AJ, Finegold M, Goss JA. Liver transplantation for severe hepatic graft-versus-host disease: An analysis of aggregate survival data. Liver Transpl 11(5):525-531, 5/2005. PMID: 15838886.
25. Lee DA, Harris CP, Gresik VM, Rao P, Lau CC. Granulocytic sarcoma presenting as pneumonia in a child with t(8;21) acute myelogenous leukemia: diagnosis by fluorescent in situ hybridization. J Pediatr Hematol Oncol 26(7):431-4, 2004. PMID: 15218417.
26. Wang HY*, Lee DA*, Peng G, Guo Z, Li Y, Kiniwa Y, Shevach EM, Wang RF. Tumor-specific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy. Immunity 20(1):107-118 (*co-first authors), 2004. PMID: 14738769.
27. Lee DA, Molinaro GA. Activated peripheral T lymphocytes undergo apoptosis when cultured with monocytes activated by HLA class II ligation. Cell Immunol 225(2):101-112, 10/2003. PMID: 14698144.
28. Lee DA, Eby WC, Molinaro GA. HIV false positivity after hepatitis B vaccination. Lancet 339(8800):1060, 1992. PMID: 1349089.

Abstracts

1. Torikai H, Reik A, Soldner F, Yuen C, Zhou Y, Kellar D, Huls H, Warren EH, Tykodi SS, Holmes MC, Rebar EJ, Lee DA, Champlin RE, Gregory PD, Jaenisch R, Cooper LJN. Disruption of HLA Expression to Enable Allogeneic Cells To Escape Immune Recognition. ASGCT 14th Annual Meeting Oral Presentation, 5/2011.
2. Somanchi SS, Cooper LJN, Lee DA. Expression of Membrane Bound GD2 Peptide Mimic on K562 Cell Line Supports Antigen Specific Expansion of T Cells Modified with GD2 Chimeric Antigen Receptor. ASGCT 14th Annual Meeting, Seattle, WA, 5/2011.
3. Ang SO, Hartline C, Tiejuan M, Maiti SN, Jackson GW, Huls H, Shpall E, Lee DA, Champlin RE, Cooper LJN. Generating a Chimeric Antigen Receptor to Redirect T-cell Specificity After Infusion. ASGCT 14th Annual Meeting Oral Presentation, Seattle, WA. e-Pub 5/2011.
4. Rosoff H, Senyukov V, Torikai H, Reik A, Littman N, Gregory PD, Holmes MC, Rebar EJ, Cooper LJN, Lee Dean A. Generation of an HLA-negative K562 Clone as Proof-of-Principle for Targeting of HLA-C by a Novel Zinc-Finger Nuclease. ASGCT 14th Annual Meeting, Seattle, WA, 5/2011.
5. Senyukov S, Denman CJ, Cooper LJN, Lee DA. IL-21 has an anti-apoptotic effect on NK cells during activation. ASGCT 14th Annual Meeting, Seattle, WA, 5/2011.
6. Ray A, Somanchi S, Lee Dean A. Enhancement of NK Cell Function and Proliferation using Liposomal MTP PE. American Society of Pediatric Hematology/Oncology, Baltimore, MD, 4/2011.
7. Phatarpekar P, Zhu S, Denman CJ, Nguyen-Jackson N, Watowich SS, Cooper LJN, Lee DA. STAT3 Activation Promotes NK Cell Proliferation, NKG2D Expression and NK Cell Antitumor Activity. 2011 Keystone Symposium, Breckenridge, CO, 1/2011.
8. Champlin R, Lee DA, Fernandez-Vina M, Rondon G, McAdams P, Julianne C, Qazilbash MH, Kebriaei P, Parmar S, Shpall EJ, Popat U, Alouis A, Ciurea SO, Cooper L, Peter T, McMannis J. Alloreactive NK Cells to Augment Antileukemia Cytotoxicity with Allogeneic Stem Cell Transplantation for Aml/Mds: A Phase I Study. 52nd Annual ASH Meeting and Exposition, Orlando, FL, 12/2010.
9. Sha N, Xing D, Lee DA, Cooper LJN, Decker W, Li S, Robinson S, Yang H, Parmar S, Tung S, Wang M, Champlin R, Bollard CM, Shpall EJ. Antigen Presenting Cell-Mediated Ex Vivo Expansion of Human Umbilical Cord Blood Cells Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. 52nd ASH Annual Meeting and Exposition, Orlando, FL, 12/2010.
10. Choi Y, Li Z, Wang X, Li H, Li F, Lee DY, Bhatnagar P, Tung CH, Biswal SL, Lee DA. Combination of Gene Therapy and Nanoparticle Imaging for Improving T-Cell Therapy. 52nd ASH Annual Meeting and Exposition, Orlando, FL, 12/2010.
11. Torikai H, Reik A, Zhou Y, Kellar D, Huls H, Warren II EH, Tykodi SS, Gregory PD, Holmes MC, Rebar EJ, Lee DA, Champlin RE, Bonni C, Cooper L. HLA and TCR Knockout by Zinc Finger Nucleases: Toward "off-the-shelf" Allogeneic T-Cell Therapy for CD19+ Malignances. 52nd ASH Annual Meeting and Exposition, Orlando, FL, 12/2010.
12. Ang S, Da Silva ML, Dawson M, Figliola M, Maiti S, Huls H, Shpall EJ, Champlin R, Lee DA, Silla L, Cooper LJN. NK Cell Proliferation and Cytolytic functions are Compromised in the Hypoxic Tumor Microenvironment. 52nd ASH Annual Meeting and Exposition, Orlando, FL, 12/2010.
13. Phatarpekar PV, Zhu S, Denman CJ, Somanchi SS, Senyukov V, Gururajan A, Cooper LJN, Lee DA. Role of STAT3 in ex-vivo expansion and activation of NK cells. 2nd annual International Conference on Immunotherapy in Pediatric Oncology, 10/2010.
14. Kellar D, Ang S, Olivares S, Dawson M, Filliola M, Huls H, Lee D, Champlin R, Cooper L. CD56+ T Cells Cp-Expressing a DC56-Specific Chimeric Antigen Receptor Can Target CD56+ Malignancies Without Autolysis. Plenary Session: America Society of Bone Marrow Transplantation 2010, 2/2010.
15. Keller D, Ang S, Olivares S, Dawson M, Figliola M, Huls H, Lee D, Champlin R, Cooper L. CD56+ T Cells Co-Expressing a CD56-Specific Chimeric Antigen Receptor Can Target CD56+ Malignancies Without Autolysis. 2010 American Society of Bone Marrow Transplantation Meeting, 2010.
16. Choi Y, Torikai H, Lee DY, Li Z, Lo D, Qin G, Tung CH, Tasciotti E, Raphael R, Biswal SL, Ang S, Lee DA, Li KC, Cooper LJN. Combining gene therapy and nanomedicine to enhance the therapeutic potential of T cells. TechConnect World Conference and Expo, 2010.
17. Fruge E, Margolin J, Horton T, Venkateswaran L, Lee D, Yee DL, Mahoney D. Defining and Managing Career Challenges for Mid-Career and Senior Stage Pediatric Hematologist/Oncologists. 2010 Annual Meeting, American Society of Pediatric Hematology/Oncology, 2010.
18. Somanchi S, Gururajan A, Cooper LJN, Lee DA. NK-Cell Acquisition of Chemokine Receptors From Engineered Antigen Presenting Cells. 52nd ASH Annual Meeting and Exposition, Orlando, FL, 2010.
19. Denman CJ, Senyukov VV, Somanchi SS, Kopp LM, Lima da Silva M, Singh H, Hurton L, Olivares S, Maiti S, Huls MH, Champlin RE, Cooper LJN, Lee DA. Robust and sustained ex vivo expansion of NK cells with artificial APCs bearing membrane-bound IL-21 is associated with a distinct phenotype and transcriptional profile. American Society for Gene and Cell Therapy Annual Meeting, 2010.
20. Phatarpekar P, Zhu S, Denman CJ, Nguyen-Jackson N, Watowich SS, Cooper LJN, Lee DA. STAT3 Activation Promotes NK Cell Proliferation, NKG2D Expression, and NK Cell Antitumor Activity. 52nd ASH Annual Meeting and Exposition, Orlando, FL, 2010.
21. Worth LL, Andersson BS, Kazerooni R, Petropouolos D, Kelly SS, Lee DA, Du M, Madden TL, deLima MJ, Champlin RE, Cooper LJN. Thiotepa (Tt), Busulfan (Bu), and Clofarabine (Clo) as a Conditioning Therapy for Allogeneic Hematopoetic Stem Cell Transplant for Patients with High Risk Malignancies Early Response and Engraftment Data. 2010 American Society of Bone Marrow Transplantation Meeting, 2010.

Book Chapters

1. Lee DA, Mahoney D. Emergencies in pediatric cancer patients. In: UpToDate, Rose, BD (Ed): Wellesley, MA, 2011.
2. Hurwitz RL, Lee DA. Childhood lead poisoning: Clinical manifestations and diagnosis. In: UpToDate, Rose, BD (Ed): Wellesley, MA, 2002.
3. Lee DA, Hurwitz RL. Childhood lead poisoning: Exposure and prevention. In: UpToDate, Rose, BD (Ed): Wellesley, MA, 2002.
4. Hurwitz RL, Lee DA. Childhood lead poisoning: Treatment. In: UpToDate, Rose, BD (Ed): Wellesley, MA, 2002.

Books (edited and written)

1. Baker DW, Elwin-Jasionowski SC, Lee DA. Talking and Listening. In: N/A. LLU Office of Diversity: Loma Linda, CA, 1994.

Letters to the Editor

1. Molinaro GA, Lee DA, Parashar UD. Rotavirus vaccines. N Engl J Med 354(16):1747-1751, 2006. PMID: 16625014.
2. Lee DA, Mueller BU. Long-term use of hydroxyurea for sickle cell anemia. JAMA 290(6):753-754 (2003 ISI IF 21.455), 8/2003. PMID: 12915425.
3. Lee DA. Home Delivery. The New Physician 12:3, 1993.

Grant & Contract Support

Title: Single-Cell Biomarkers of Clinical-Grade T Cells and NK Cells to Optimize Tumor Immunotherapy
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Principal Investigator
Principal Investigator: Navin Varadarajan
Duration: 12/1/2012 - 11/30/2015
 
Title: Aerosol IL-2: Feasibility in OS patients 12-18 yrs and for lung NK cel expansion
Funding Source: NIH/NCI
Role: Co-Principal Investigator
Principal Investigator: Kleinerman, Eugenie
Duration: 8/1/2012 - 7/30/2017
 
Title: Engineering Natural Killer Cells for Anti-Leukemia Therapy
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 4/1/2012 - 3/31/2017
 
Title: 19F Imaging of Adoptively Transferred NK Cells
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Eric Ahrens
Duration: 4/1/2012 - 3/30/2014
 
Title: Program for NK-cell therapies for pediatric Malignancies
Funding Source: Hyundai Hope on Wheels
Role: Co-Investigator
Principal Investigator: Cooper, Laurence J. N.
Duration: 1/1/2012 - 12/31/2012
 
Title: Multi-function nanoparticles to image clinical-grade T cells and NK cells
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator
Principal Investigator: Cooper, Laurence J. N.
Duration: 12/1/2011 - 11/30/2013
 
Title: NK-Cell Immunotherapy for NHL
Funding Source: Lymphoma Research Foundation
Role: Principal Investigator
Duration: 11/1/2011 - 10/31/2014
 
Title: NK-Cell Immunotherapy for NHL
Funding Source: Leukemia and Lymphoma Society
Role: Principal Investigator
Duration: 10/1/2011 - 9/30/2014
 
Title: A Single-center Open-label Phase 1 Study of ALT-801 for ex vivo Maturation and in vivo Retargeting of Haploidentical Natural Killer Cells Delivered Following Fludarabine, Cytarabine and G-CSF in Patients with Relapsed/Refractory Acute Myeloid Leukemia
Funding Source: Altor BioScience Corporation
Role: Principal Investigator
Duration: 7/2011 - 6/2014
 
Title: Synergy between histone deacetylase inhibitors and natural killer cells for the treatment of relapsed bone sarcomas
Funding Source: Sunbeam Foundations
Role: Principal Investigator
Duration: 7/1/2011 - 6/30/2012
 
Title: Immunotherapy Research Award
Funding Source: Farrah Fawcett Foundation
Role: Principal Investigator
Duration: 7/1/2011 - 6/30/2012
 
Title: NK Cells for Bone Tumors
Funding Source: The Shannon Wilkes Osteosarcoma
Role: Principal Investigator
Duration: 7/1/2011 - 6/30/2012
 
Title: Cellular Therapy for Cancer (total) Adoptive Immunotherapy with NK Cells Expanded ex vivo for Treatment of AML (project 3)
Funding Source: Cancer Prevention & Research Institute of Texas (CPRIT)
Role: Co-Investigator on project 3
Principal Investigator: Brenner, Malcolm
Duration: 5/1/2011 - 4/30/2016
 
Title: Expanded NK Cells for Adoptive Immunotherapy
Funding Source: BD Biosciences
Role: Principal Investigator
Duration: 5/1/2011 - 5/1/2012
 
Title: A Phase I Study of ALT-801 for Maturation and Retargeting of Haploidentical NK Cells Against AML: FDA BB-IND 13846
Funding Source: Food and Drug Administration (FDA)
Role: Principal Investigator
Duration: 11/1/2010 - 10/31/2012
 
Title: Genetic and epigenetic modification of NK cells against pediatric cancer
Funding Source: St. Baldrick's Scholar (CDA) Award
Role: Principal Investigator
Duration: 7/1/2009 - 6/30/2014
 
Title: Innate Immune Effects of Post-Stem Cell Transplant Vidaza
Funding Source: Celgene Corporation
Role: Principal Investigator
Duration: 5/2009 - 4/2014
 
Title: Optimized immunogene therapy for AML
Funding Source: UT MD Anderson Cancer Center
Role: Principal Investigator
Duration: 3/1/2008 - 8/31/2012
 
Title: Pediatric Oncology Clinical Research Training Program
Funding Source: NIH/NCI
Role: Trainee
Principal Investigator: David Poplack
Duration: 7/1/2003 - 6/30/2006

Last updated: 5/15/2014